Kathrin Meyer, PhD

Kathrin Meyer, PhD

Physical Medicine and Rehabilitation

Assistant Professor

Profile

Dr. Meyer studied molecular and cellular biology at the University of Bern, Switzerland followed by a post-doctoral fellowship at Nationwide Children’s Hospital, Columbus Ohio, USA developing different therapeutic approaches for the neuromuscular disease Spinal Muscular Atrophy including the now-approved AAV gene therapy Zolgensma. Dr. Meyers research as Principal Investigator at Nationwide Children's Hospital and Assistant Professor at The Ohio State University focused on the development of novel in vitro models for neurological diseases and testing of novel therapeutics. She also optimized cerebrospinal fluid delivery methods for therapeutics including AAV and successfully translated several programs to clinical trials. She serves on several scientific advisory boards for patient foundations and as Chief Scientific Officer at Alcyone Therapeutics.

Academic Information

Assistant Professor

Research Interests

  • Molecular disease mechanisms and common pathways affected in neurodevelopmental disorders
  • Impact of patient-specific disease modifiers on disease manifestation
  • Development of adeno-associated viral vector gene therapy
  • Develop promoter modulation and RNA splicing as therapeutics
  • Improve uptake of therapeutics to the CNS

Education & Training

Degrees

2010 PhD, University of Berne
2006 MA, Institute of Cell Biology, University of Berne
2002 BA, Institute of Educational Science, University of Berne

Awards & Honors

  • 2015: Young Investigator Development Award, Muscular Dystrophy Association
  • 2013: Ohio State Muscle Group Travel Award
  • 2012: Swiss National Science Foundation Fellowship Award for Advanced Researchers
  • 2010: Swiss National Science Foundation Fellowship Award for Perspective Researchers
  • 2010: Best PhD Thesis Award Cellular and Biomedical Science Faculty, University of Berne, Switzerland

Publications

  • Johnson TB, Brudvig JJ, Likhite S, Pratt MA, White KA, Cain JT, Booth CD, Timm DJ, Davis SS, Meyerink B, Pineda R, Dennys-Rivers C, Kaspar BK, Meyer K, Weimer JM.
    Early postnatal administration of an AAV9 gene therapy is safe and efficacious in CLN3 disease.
    Front Genet. 2023;14:1118649. doi: 10.3389/fgene.2023.1118649. eCollection 2023. PubMed PMID: 37035740; PubMed Central PMCID: PMC10080320.
  • Sierra-Delgado JA, Likhite S, Bautista PK, Gómez-Ochoa SA, Echeverría LE, Guío E, Vargas C, Serrano NC, Meyer KC, Rincon MY.
    Prevalence of Neutralizing Antibodies against Adeno-Associated Virus Serotypes 1, 2, and 9 in Non-Injected Latin American Patients with Heart Failure-ANVIAS Study.
    Int J Mol Sci. 2023 Mar 14;24(6). doi: 10.3390/ijms24065579. PubMed PMID: 36982654; PubMed Central PMCID: PMC10051173.
  • Dennys CN, Roussel F, Rodrigo R, Zhang X, Sierra Delgado A, Hartlaub A, Saelim-Ector A, Ray W, Heintzman S, Fox A, Kolb SJ, Beckman J, Franco MC, Meyer K.
    CuATSM effectively ameliorates ALS patient astrocyte-mediated motor neuron toxicity in human in vitro models of amyotrophic lateral sclerosis.
    Glia. 2022 Oct 10;. doi: 10.1002/glia.24278. [Epub ahead of print] PubMed PMID: 36213964.
    • This article was featured in ALS today: New Study Uncovers Mechanism of CuATSM, ALS Therapy Now in Trials | Findings May Help ID ALS Patients Most Likely to Respond to Treatment | ALS News Today
  • Sinha Ray S, Dutta D, Dennys C, Powers S, Roussel F, Lisowski P, Glažar P, Zhang X, Biswas P, Caporale JR, Rajewsky N, Bickle M, Wein N, Bellen HJ, Likhite S, Marcogliese PC, Meyer KC.
    Mechanisms of IRF2BPL-related disorders and identification of a potential therapeutic strategy.
    Cell Rep. 2022 Dec 6;41(10):111751. doi: 10.1016/j.celrep.2022.111751. PMID: 36476864.
  • Holmes AD, White KA, Pratt MA, Johnson TB, Likhite S, Meyer K, Weimer JM.
    Sex-split analysis of pathology and motor-behavioral outcomes in a mouse model of CLN8-Batten disease reveals an increased disease burden and trajectory in female Cln8mnd mice.
    Orphanet J Rare Dis. 2022 Nov 11;17(1):411. doi: 10.1186/s13023-022-02564-7. PMID: 36369162; PMCID: PMC9652919.
  • Pilotto F, Schmitz A, Maharjan N, Diab R, Odriozola A, Tripathi P, Yamoah A, Scheidegger O, Oestmann A, Dennys CN, Sinha Ray S, Rodrigo R, Kolb S, Aronica E, Di Santo S, Widmer HR, Charlet-Berguerand N, Selvaraj BT, Chandran S, Meyer K, Zuber B, Goswami A, Weis J, Saxena S.
    PolyGA targets the ER stress-adaptive response by impairing GRP75 function at the MAM in C9ORF72-ALS/FTD.
    Acta Neuropathol. 2022 Nov;144(5):939-966. doi: 10.1007/s00401-022-02494-5. Epub 2022 Sep 19. PubMed PMID: 36121477; PubMed Central PMCID: PMC9547809.
  • Dennys C, Baggio C, Rodrigo R, Roussel F, Kulinich A, Heintzman S, Fox A, Kolb SJ, Shaw PJ, Ethell IM, Pellecchia M, Meyer KC.
    EphA4 targeting agents protect motor neurons from cell death induced by amyotrophic lateral sclerosis -astrocytes.
    iScience. 2022 Sep 16;25(9):104877. doi: 10.1016/j.isci.2022.104877. eCollection 2022 Sep 16. PubMed PMID: 36034213; PubMed Central PMCID: PMC9404653.
  • Liao XH, Avalos P, Shelest O, Ofan R, Shilo M, Bresee C, Likhite S, Vit JP, Heuer H, Kaspar B, Meyer K, Dumitrescu AM, Refetoff S, Svendsen CN, Vatine GD.
    AAV9-MCT8 Delivery at Juvenile Stage Ameliorates Neurological and Behavioral Deficits in a Mouse Model of MCT8-Deficiency.
    Thyroid. 2022 Jul;32(7):849-859. doi: 10.1089/thy.2022.0034. Epub 2022 May 20. PubMed PMID: 35350867; PubMed Central PMCID: PMC9469747
  • Naeimi Kararoudi M, Likhite S, Elmas E, Yamamoto K, Schwartz M, Sorathia K, de Souza Fernandes Pereira M, Sezgin Y, Devine RD, Lyberger JM, Behbehani GK, Chakravarti N, Moriarity BS, Meyer K, Lee DA.
    Optimization and validation of CAR transduction into human primary NK cells using CRISPR and AAV.
    Cell Rep Methods. 2022 Jun 13;2(6):100236. doi: 10.1016/j.crmeth.2022.100236. PMID: 35784645; PMCID: PMC9243630.